| Literature DB >> 25344657 |
Verónica Rodriguez-Nava1, Stéphane Durupt, Sandra Chyderiotis, Anne-Marie Freydière, Judith Karsenty, Michèle de Montclos, Philippe Reix, Isabelle Durieu, Raphaele Nove-Josserand, Raphael Chiron, François Bremont, Laurent Têtu, Marlène Murris, Dominique Terru, Sylvain Godreuil, Emmanuelle Bergeron, Jean Freney, Patrick Boiron, François Vandenesch, Hélène Marchandin, Christine Segonds, Anne Doléans-Jordheim.
Abstract
Some bacterial species recovered from the airways of cystic fibrosis (CF) patients are indisputably associated with lung infections, whereas the clinical relevance of others, such as Nocardia spp., remains unclear. Sixteen French CF cases of colonization/infection with Nocardia spp. were reviewed in order to evaluate the epidemiology, the clinical impact and the potential treatment of these bacteria, and results were compared to those of the literature. Five Nocardia species were identified, Nocardia cyriacigeorgica being the major species (50 % of cases). At first isolation, Nocardia was the sole pathogen recovered in six patients. Seven patients presented pulmonary exacerbation. For 12 patients, antimicrobial treatment against Nocardia was started immediately, mainly based on cotrimoxazole (6 of the 12 cases). In this study, we highlight the heterogeneity of the clinical management of Nocardia spp. in CF. Guidelines for the clinical management of Nocardia infections in CF patients are proposed.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25344657 DOI: 10.1007/s00430-014-0360-3
Source DB: PubMed Journal: Med Microbiol Immunol ISSN: 0300-8584 Impact factor: 3.402